# v4.19

## Related releases

## Data changes

### Alteration

```
POLD1 S478N, Mutation Effect, Description Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations) Added
POLD1 304_533mis [Exonuclease domain missense mutations] Deleted
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations) Added
POLE 268_471mis [Exonuclease domain missense mutations] Deleted
```

### Evidence

```
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Summary Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Dostarlimab, Description Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Dostarlimab, FDA Level Updated
	 New: Fda2
	 Old: no
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Dostarlimab, Level Updated
	 New: 2
	 Old:
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Dostarlimab, Propagation to Other Liquid Tumor Types Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Dostarlimab, Propagation to Other Solid Tumor Types Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Dostarlimab 2 Added
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Dostarlimab, FDA Level Updated
	 New: Fda2
	 Old:
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Ipilimumab + Nivolumab, Description Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Ipilimumab + Nivolumab, FDA Level Updated
	 New: Fda2
	 Old: no
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Ipilimumab + Nivolumab, Level Updated
	 New: 2
	 Old:
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Ipilimumab + Nivolumab, Propagation to Other Liquid Tumor Types Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Ipilimumab + Nivolumab, Propagation to Other Solid Tumor Types Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Ipilimumab + Nivolumab 2 Added
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Ipilimumab + Nivolumab, FDA Level Updated
	 New: Fda2
	 Old:
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Nivolumab, Description Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Nivolumab, FDA Level Updated
	 New: Fda2
	 Old: no
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Nivolumab, Level Updated
	 New: 2
	 Old:
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Nivolumab, Propagation to Other Liquid Tumor Types Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Nivolumab, Propagation to Other Solid Tumor Types Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Nivolumab 2 Added
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Nivolumab, FDA Level Updated
	 New: Fda2
	 Old:
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Pembrolizumab, Description Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Pembrolizumab, FDA Level Updated
	 New: Fda2
	 Old: no
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Pembrolizumab, Level Updated
	 New: 2
	 Old:
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Pembrolizumab, Propagation to Other Liquid Tumor Types Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Pembrolizumab, Propagation to Other Solid Tumor Types Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Pembrolizumab, Additional Information Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer Added
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Dostarlimab, Name Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Ipilimumab + Nivolumab, Name Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Nivolumab, Name Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Pembrolizumab, Name Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Pembrolizumab, FDA Level Updated
	 New: Fda2
	 Old:
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Pembrolizumab 2 Added
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Summary Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Dostarlimab, Description Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Dostarlimab, FDA Level Updated
	 New: Fda2
	 Old: no
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Dostarlimab, Level Updated
	 New: 2
	 Old:
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Dostarlimab, Propagation to Other Liquid Tumor Types Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Dostarlimab, Propagation to Other Solid Tumor Types Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Dostarlimab, Additional Information Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Dostarlimab 2 Added
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Dostarlimab, FDA Level Updated
	 New: Fda2
	 Old:
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Ipilimumab + Nivolumab, Description Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Ipilimumab + Nivolumab, FDA Level Updated
	 New: Fda2
	 Old: no
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Ipilimumab + Nivolumab, Level Updated
	 New: 2
	 Old:
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Ipilimumab + Nivolumab, Propagation to Other Liquid Tumor Types Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Ipilimumab + Nivolumab, Propagation to Other Solid Tumor Types Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Ipilimumab + Nivolumab 2 Added
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Ipilimumab + Nivolumab, FDA Level Updated
	 New: Fda2
	 Old:
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Nivolumab, Description Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Nivolumab, FDA Level Updated
	 New: Fda2
	 Old: no
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Nivolumab, Level Updated
	 New: 2
	 Old:
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Nivolumab, Propagation to Other Liquid Tumor Types Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Nivolumab, Propagation to Other Solid Tumor Types Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Nivolumab 2 Added
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Nivolumab, FDA Level Updated
	 New: Fda2
	 Old:
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Pembrolizumab, Description Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Pembrolizumab, FDA Level Updated
	 New: Fda2
	 Old: no
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Pembrolizumab, Level Updated
	 New: 2
	 Old:
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Pembrolizumab, Propagation to Other Liquid Tumor Types Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Pembrolizumab, Propagation to Other Solid Tumor Types Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer Added
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Dostarlimab, Name Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Ipilimumab + Nivolumab, Name Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Nivolumab, Name Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Pembrolizumab, Name Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Pembrolizumab, FDA Level Updated
	 New: Fda2
	 Old:
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Pembrolizumab 2 Added
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Other Solid Tumor Types, Summary Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Colorectal Cancer, Name Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Small Bowel Cancer, Name Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Other Solid Tumor Types, Name Updated
POLD1 E318K, S478N, D402N (Oncogenic Exonuclease Domain Missense Mutations), Other Solid Tumor Types Added
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Summary Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Dostarlimab, Description Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Dostarlimab, FDA Level Updated
	 New: Fda2
	 Old: no
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Dostarlimab, Level Updated
	 New: 2
	 Old:
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Dostarlimab, Propagation to Other Liquid Tumor Types Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Dostarlimab, Propagation to Other Solid Tumor Types Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Dostarlimab, Additional Information Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Dostarlimab 2 Added
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Dostarlimab, FDA Level Updated
	 New: Fda2
	 Old:
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Ipilimumab + Nivolumab, Description Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Ipilimumab + Nivolumab, FDA Level Updated
	 New: Fda2
	 Old: no
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Ipilimumab + Nivolumab, Level Updated
	 New: 2
	 Old:
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Ipilimumab + Nivolumab, Propagation to Other Liquid Tumor Types Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Ipilimumab + Nivolumab, Propagation to Other Solid Tumor Types Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Ipilimumab + Nivolumab 2 Added
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Ipilimumab + Nivolumab, FDA Level Updated
	 New: Fda2
	 Old:
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Nivolumab, Description Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Nivolumab, FDA Level Updated
	 New: Fda2
	 Old: no
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Nivolumab, Level Updated
	 New: 2
	 Old:
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Nivolumab, Propagation to Other Liquid Tumor Types Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Nivolumab, Propagation to Other Solid Tumor Types Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Nivolumab 2 Added
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Nivolumab, FDA Level Updated
	 New: Fda2
	 Old:
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Pembrolizumab, Description Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Pembrolizumab, FDA Level Updated
	 New: Fda2
	 Old: no
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Pembrolizumab, Level Updated
	 New: 2
	 Old:
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Pembrolizumab, Propagation to Other Liquid Tumor Types Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Pembrolizumab, Propagation to Other Solid Tumor Types Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Pembrolizumab, Additional Information Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer Added
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Dostarlimab, Name Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Ipilimumab + Nivolumab, Name Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Nivolumab, Name Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Pembrolizumab, Name Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Pembrolizumab, FDA Level Updated
	 New: Fda2
	 Old:
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Pembrolizumab 2 Added
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Summary Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Dostarlimab, Description Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Dostarlimab, FDA Level Updated
	 New: Fda2
	 Old: no
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Dostarlimab, Level Updated
	 New: 2
	 Old:
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Dostarlimab, Propagation to Other Liquid Tumor Types Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Dostarlimab, Propagation to Other Solid Tumor Types Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Dostarlimab, Additional Information Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Dostarlimab 2 Added
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Dostarlimab, FDA Level Updated
	 New: Fda2
	 Old:
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Ipilimumab + Nivolumab, Description Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Ipilimumab + Nivolumab, FDA Level Updated
	 New: Fda2
	 Old: no
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Ipilimumab + Nivolumab, Level Updated
	 New: 2
	 Old:
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Ipilimumab + Nivolumab, Propagation to Other Liquid Tumor Types Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Ipilimumab + Nivolumab, Propagation to Other Solid Tumor Types Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Ipilimumab + Nivolumab 2 Added
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Ipilimumab + Nivolumab, FDA Level Updated
	 New: Fda2
	 Old:
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Nivolumab, Description Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Nivolumab, FDA Level Updated
	 New: Fda2
	 Old: no
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Nivolumab, Level Updated
	 New: 2
	 Old:
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Nivolumab, Propagation to Other Liquid Tumor Types Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Nivolumab, Propagation to Other Solid Tumor Types Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Nivolumab 2 Added
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Nivolumab, FDA Level Updated
	 New: Fda2
	 Old:
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Pembrolizumab, Description Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Pembrolizumab, FDA Level Updated
	 New: Fda2
	 Old: no
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Pembrolizumab, Level Updated
	 New: 2
	 Old:
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Pembrolizumab, Propagation to Other Liquid Tumor Types Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Pembrolizumab, Propagation to Other Solid Tumor Types Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer Added
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Dostarlimab, Name Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Ipilimumab + Nivolumab, Name Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Nivolumab, Name Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Pembrolizumab, Name Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Pembrolizumab, FDA Level Updated
	 New: Fda2
	 Old:
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Pembrolizumab 2 Added
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Other Solid Tumor Types, Summary Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Colorectal Cancer, Name Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Small Bowel Cancer, Name Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Other Solid Tumor Types, Name Updated
POLE A288V, A456P, A463D, A463T, A463V, D275A, D275G, D275V, D368N, D368Y, F367L, F367S, F367V, K425R, L424I, L424V, M295R, M444K, P286H, P286L, P286R, P286S, P436H, P436R, P436S, S297F, S297Y, S459F, S459Y, S461L, S461P, S461T, V411L, V411M, V464A, Y458C, Y458H (Oncogenic exonuclease domain missense mutations), Other Solid Tumor Types Added
```
